U.S. markets closed

Invitae Corporation (NVTA)

NYSE - NYSE Delayed Price. Currency in USD
2.7800-0.0400 (-1.42%)
At close: 01:00PM EST
2.7800 0.00 (0.00%)
After hours: 04:54PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.8200
Bid2.7900 x 2200
Ask2.8000 x 4000
Day's Range2.7100 - 2.8100
52 Week Range1.8300 - 18.4400
Avg. Volume9,662,714
Market Cap675.251M
Beta (5Y Monthly)1.58
PE Ratio (TTM)N/A
EPS (TTM)-2.0560
Earnings DateFeb 22, 2023 - Feb 27, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.84
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NVTA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Invitae Corporation
    MYGN: Lowering target price to $20.00MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Fair Value
    Economic Moat
    4 days agoArgus Research
View more
  • Motley Fool

    Why Shares of Invitae Rose 11% on Tuesday

    Shares of medical genetics testing company Invitae (NYSE: NVTA) rose 11% on Tuesday. Invitate didn't have any announcements on Tuesday, though it is presenting research this week in Nashville, Tennessee, at the National Society of Genetic Counselors conference. Invitae reported revenue of $133.5 million, up 16.7%, year over year.

  • Motley Fool

    More Likely to 5X First: Teladoc vs. Invitae

    Two stocks that could climb fivefold if they make progress toward their goals are Teladoc Health (NYSE: TDOC) and Invitae (NYSE: NVTA). Teladoc and Invitae shares both have lost more than 70% this year. Teladoc disappointed investors with two massive noncash goodwill impairment charges linked to an acquisition.

  • PR Newswire

    Invitae Showcases Advances in Medical Genomics at the National Society of Genetic Counselors (NSGC) 41st Annual Conference

    Researchers from Invitae (NYSE: NVTA), a leading medical genetics company, are presenting research next week at the National Society of Genetic Counselors (NSGC) 41st Annual Conference in Nashville enabling the progress of the science and practice of genetics in patient care. In addition to its research presentations, the company will present the Heart of Genetic Counseling Award, which recognizes excellence in the field of genetic counseling.